Recombinant bovine αs1-casein ameliorates PCPA-induced insomnia-like behavioral and physiological abnormalities in mice.

Authors

Xiang-Li Mu, Yan Sun, Meng-Jia Song, Lin-Lin Ding, Jing-Yang Cai, Ai-Mei Liao, Yin-Chen Hou, Ji-Hong Huang, Guang-Hai Yu, Long Pan

Published in

Food & function. Oct 15, 2026. Epub Oct 15, 2026.

Abstract

Insomnia is a multifactorial sleep-wake disorder associated with altered neurotransmitter homeostasis, systemic inflammatory changes, and gut microbial dysbiosis. Recombinant bovine αs1-casein (RC) is a scalable milk-protein ingredient, but its effects on insomnia-like physiological and behavioral abnormalities have not been systematically evaluated. We investigated RC in a p-chlorophenylalanine (PCPA)-induced mouse model. Male ICR mice received RC (100, 300, or 500 mg kg^-1 day^-1), melatonin, Naoxinshu oral liquid, natural casein, or vehicle for 7 days after PCPA modeling. Body weight, open-field behavior, serum cytokines, brain neurotransmitters, hippocampal histology, organ indices, and cecal microbiota were assessed. RC improved body-weight recovery and open-field performance without altering major-organ indices. It increased brain 5-HT, 5-HIAA, dopamine, GABA, and glutamate concentrations and reduced the elevated norepinephrine concentration. High-dose RC reduced serum IL-6 and was associated with better-preserved hippocampal morphology. 16S rRNA gene sequencing showed RC-associated changes in bacterial richness and community structure. The parallel physiological, neurochemical, inflammatory, and microbial changes support an association between RC administration and improvement of PCPA-induced insomnia-like abnormalities. These results identify recombinant bovine αs1-casein as a promising food-derived ingredient for further investigation in sleep-health applications, while the microbiota-gut-brain axis is presented as a testable mechanistic framework rather than a demonstrated causal pathway.

PMID:
42878146
Bibliographic data and abstract were imported from PubMed on 16 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.